US Patent Issued to Precision Biologics on Nov. 4 for "Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers" (Maryland, New York Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,460,013, issued on Nov. 4, was assigned to Precision Biologics Inc. (Bethesda, Md.).

"Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers" was invented by Myron Arlen (Great Neck, N.Y.), J. Andrew Bristol (Rockville, Md.), Ariel Hollinshead (Bethesda, Md.) and Kwong Tsang (Bethesda, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present relates to monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibodies, and the use of these monoclonal antibodies in cancer treatment and detection."

The patent was fil...